Texas News Studio- NYC Monkeypox – https://youtu.be/c5XqtF4HfB0
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness.
Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
The vaccine is approved under the brand name Jynneos in the U.S. with a label that also specifically covers monkeypox. Because monkeypox virus is closely related to the variola virus that causes smallpox, smallpox vaccines can also protect against monkeypox, the Centers for Disease Control and Prevention (CDC) says.
JYNNEOS was approved by the US Food and Drug Administration (FDA) in September 2019 for the prevention of smallpox and monkeypox in adults. It is the only FDA-approved non-replicating smallpox and monkeypox vaccine and the only approved monkeypox vaccine in the world.
JYNNEOS mechanism of action and dosage
JYNNEOS contains a live, attenuated form of the vaccinia virus called Modified Vaccinia Ankara (MVA), which is similar to variola or monkeypox viruses but is less harmful. It is non-replicating and capable of generating humoral and cellular immune responses to orthopoxviruses.
Marketing commentary on Bavarian Nordic
Bavarian Nordic is a Denmark-based biotechnology company involved in the development of innovative drugs and vaccines for the treatment of infectious diseases and cancer.
The company has a portfolio of cancer therapies and vaccine candidates under development for Ebola, Human papillomavirus, hepatitis B and human immunodeficiency virus (HIV).
References Below Linked to Covid 19 Vaccines and Gene Editing Related to Modified Vaccinia Virus Ankara (MVA)
COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
Modified vaccinia virus Ankara as a vector for suicide gene therapy
Modified vaccinia virus Ankara (MVA) has been used successfully to express various antigens for the development of vaccines. Here we show that MVA can also be used as an efficient vector for the transfer of suicide genes to cancer cells.
We have generated a new and highly potent suicide gene, FCU1, which encodes a fusion protein derived from the yeast cytosine deaminase and uracil phosphoribosyltransferase genes. We now describe the therapeutic benefit of using MVA to deliver and express the FCU1 gene in cancer cells.
MVA-mediated transfer of the FCU1 gene to various human tumor cells results in the production of a bifunctional intracellular (located or occurring within a cell or cells) enzyme, such that exposure to the prodrug 5-FC suppresses the growth of the tumor cells both in vitro and in vivo.
Moreover, we report a more potent tumor growth delay at lower doses of 5-FC using MVA-FCU1 in comparison to adenovirus encoding FCU1. Prolonged therapeutic levels of cytotoxic 5-FU were detected in tumors in mice treated with both MVA-FCU1 and 5-FC while no detectable 5-FU was found in the circulation. This original combination between MVA and FCU1 represents a potentially safe and attractive therapeutic option to test in man.
The Mark of the Beast System is real and here!
Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.
#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus #Christ